Novo Nordisk's NovoSeven To Enter Clinic For Trauma Bleeding
This article was originally published in The Pink Sheet Daily
Executive Summary
A U.S. clinical trial for a trauma bleeding indication for Novo's recombinant Factor VIIa hemophilia treatment will begin within six months, the company says. FDA recently lifted a clinical hold based on European safety data.
You may also be interested in...
Novo Nordisk Pulls Unlucky NovoSeven Application In EU
Novo Nordisk will resubmit the application for its factor VIIa product for a supplemental intracerebral hemorrhage indication.
Merck Tax Settlement Could Be Smaller Than GSK’s $3.4 Bil. IRS Deal
A possible settlement between Merck and tax authorities could be significantly smaller than GlaxoSmithKline's recent settlement with the IRS based on the companies' projected liability